ZONHONBIO (ZONHON BIOPHARMA INSTITUTE, INC.) located in Changzhou National High-tech Development Zone was co-founded in August 2011 by QIANHONG BIO-PHARMA (CHANGZHOU QIANHONG BIOPHARMA CO., LTD., SZSE:002550) and an international research and development team led by academicians and state specially recruited experts. ZONHONBIO aims to be an independent and innovative bio-pharmaceutical company with advanced biotechnology, progressive management model and congenial enterprise culture.

ZONHONBIO is a clinical-stage pharmaceutical enterprise, which focuses on the desensitization therapy for allergic diseases and the biological therapy for central nervous system, cardiac cerebral pneumal and vascular diseases and intractable solid tumors, having a fully self-developed technology and a new production line. Three subsidiaries were established successively, namely GENSUNBIO, GENHONBIO and GENSUNDO, aiming to realize the ecological closed-loop for the industrial transformation of biomedicine, new bio-materials and medical devices.

Over the years, ZONHONBIO has been awarded with honors including “National High-tech Enterprise”, “Postdoctoral Programme”, “National Intellectual Property Standard Implementing Enterprise”, “Jiangsu Intellectual Property Standard Implementing  Demonstration Enterprise”, “Gazelle Enterprise in Jiangsu Provincial High-Tech Industrial Development Zone”, “Jiangsu Research and Development Institution of Foreign Investment”, “Gazelle Enterprise in National Innovation Demonstration Zone of South Jiangsu”, “Jiangsu Engineering Research Center for Precision Biomedicines”, etc. Since the establishment of the National Postdoctoral Programme, ZONHONBIO has been consecutively honored with excellent post-doctoral workstation of Changzhou for years, and has been hornored with the title of “Jiangsu Best 10 Demonstration Post-doctoral Research Workstation”.

With years of independent innovation, ZONHONBIO has possessed core technologies such as ZHPEG®, ZHBKKS™, ZHBody®, ZHBiAb®, ZHAIT™, ZHSLIT™, ZHPBM™, and ZHCDX™. We have applied for more than 200 domestic and international patents, among which over 100 patents have been granted, and many of them have won the title of “High-quality Patent”.

After years of hard work, ZONHONBIO has completed the technology transfer of numbers of innovative drug projects, and dozens of ongoing projects are under different stages of preclinical and clinical research. ZONHONBIO has created good social values and economic benefits.

Our aim is to build a modern biomedical research and development institution as well as an integrated industry-academia-research base that is financially successful, respected by peers, and has our own characteristics. We will try our best to write a more splendid chapter for the development of Chinese innovative biomedicine.